These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29507069)

  • 41. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
    Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
    J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
    Jiang L; Fantoni G; Couzens L; Gao J; Plant E; Ye Z; Eichelberger MC; Wan H
    J Virol; 2016 Jan; 90(1):117-28. PubMed ID: 26468531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
    Tan Y; Ng Q; Jia Q; Kwang J; He F
    J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel linear epitope crossing Group 1 and Group 2 influenza A viruses located in the helix A of HA2 derived from H7N9.
    Li Z; Wan Z; Li T; Xie Q; Sun H; Chen H; Liang G; Shao H; Qin A; Ye J
    Vet Microbiol; 2019 Jan; 228():39-44. PubMed ID: 30593378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an Alternative Modified Live Influenza B Virus Vaccine.
    Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein.
    Yoon A; Yi KS; Chang SY; Kim SH; Song M; Choi JA; Bourgeois M; Hossain MJ; Chen LM; Donis RO; Kim H; Lee Y; Hwang DB; Min JY; Chang SJ; Chung J
    PLoS One; 2015; 10(10):e0141312. PubMed ID: 26512723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses.
    Wang W; Sun X; Li Y; Su J; Ling Z; Zhang T; Wang F; Zhang H; Chen H; Ding J; Sun B
    Nat Commun; 2016 Dec; 7():13577. PubMed ID: 27910950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of monoclonal antibodies reactive against subtype specific conserved B-cell epitopes on haemagglutinin protein of influenza virus H5N1.
    Fiebig P; Shehata AA; Liebert UG
    Virus Res; 2015 Mar; 199():46-55. PubMed ID: 25599601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of cross-clade monoclonal antibodies against H5N1 highly pathogenic avian influenza virus and their application to the antigenic analysis of diverse H5 subtype viruses.
    Gronsang D; Bui AN; Trinh DQ; Bui VN; Nguyen KV; Can MX; Omatsu T; Mizutani T; Nagai M; Katayama Y; Thampaisarn R; Ogawa H; Imai K
    Arch Virol; 2017 Aug; 162(8):2257-2269. PubMed ID: 28405766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preparation and characterization of egg yolk immunoglobulin Y specific to influenza B virus.
    Wen J; Zhao S; He D; Yang Y; Li Y; Zhu S
    Antiviral Res; 2012 Jan; 93(1):154-9. PubMed ID: 22127067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
    Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
    PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and characterization of neutralizing monoclonal antibodies against the S1 subunit protein of QX-like avian infectious bronchitis virus strain Sczy3.
    Zou N; Wang F; Duan Z; Xia J; Wen X; Yan Q; Liu P; Cao S; Huang Y
    Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):17-24. PubMed ID: 25723279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
    Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
    Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion.
    Gong X; Yin H; Shi Y; Guan S; He X; Yang L; Yu Y; Kuai Z; Jiang C; Kong W; Wang S; Shan Y
    Immunol Lett; 2016 Apr; 172():11-20. PubMed ID: 26875772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.
    Gray SA; Moore M; VandenEkart EJ; Roque RP; Bowen RA; Van Hoeven N; Wiley SR; Clegg CH
    Antiviral Res; 2016 Jul; 131():100-8. PubMed ID: 27109194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.
    Chai N; Swem LR; Park S; Nakamura G; Chiang N; Estevez A; Fong R; Kamen L; Kho E; Reichelt M; Lin Z; Chiu H; Skippington E; Modrusan Z; Stinson J; Xu M; Lupardus P; Ciferri C; Tan MW
    Nat Commun; 2017 Jan; 8():14234. PubMed ID: 28102191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man.
    Okada J; Ohshima N; Kubota-Koketsu R; Iba Y; Ota S; Takase W; Yoshikawa T; Ishikawa T; Asano Y; Okuno Y; Kurosawa Y
    J Gen Virol; 2011 Feb; 92(Pt 2):326-35. PubMed ID: 21068214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigenic variants with amino acid deletions clarify a neutralizing epitope specific for influenza B virus Victoria group strains.
    Nakagawa N; Kubota R; Nakagawa T; Okuno Y
    J Gen Virol; 2001 Sep; 82(Pt 9):2169-2172. PubMed ID: 11514726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.